BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed QURE catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:440c0d91eef2c24bb770@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:QURE P1/P2 readout (est.): GenTLE
DESCRIPTION:AMT-260 Gene Therapy Study in Adults With Unilateral Refractory
  Mesial Temporal Lobe Epilepsy\nNCT06063850 | PHASE1/PHASE2 | RECRUITING |
  sponsor: UniQure Biopharma B.V.\nPrimary completion date (ESTIMATED)\; to
 p-line results usually follow later.\nTicker QURE (confidence 0.6)\nSource
 : https://clinicaltrials.gov/study/NCT06063850\nScheduling/reference data 
 from public records\; dates can move. Not investment\, legal or medical ad
 vice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06063850
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:36071142b7f2ae81a033@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:QURE PDUFA (company-disclosed): ifezuntirgene
DESCRIPTION:PDUFA May 1\, 2027 - uniQure N.V. (ifezuntirgene)\nConfidence: 
 company-disclosed\nTicker QURE (confidence 1.0)\nSource: https://www.sec.g
 ov/Archives/edgar/data/1590560/000110465926120915/tm2628699d1_ex99-1.htm\n
 Scheduling/reference data from public records\; dates can move. Not invest
 ment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1590560/000110465926120915/tm26
 28699d1_ex99-1.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
END:VCALENDAR
